8-K: Pasithea Therapeutics Announces Positive Early Data for Cancer Drug PAS-004 in Phase 1 Trial

Pasithea Therapeutics reports positive initial safety, tolerability, pharmacokinetic, and preliminary efficacy data from its Phase 1 clinical trial of PAS-004, a novel MEK inhibitor, in advanced cancer patients.

Summary

• Pasithea Therapeutics has released initial data from its Phase 1 clinical trial of PAS-004, a new MEK inhibitor, showing promising results.
• The trial included six patients across two dose cohorts (2mg and 4mg) with advanced solid tumors.
• The drug demonstrated a favorable safety profile with no treatment-related adverse events or dose-limiting toxicities observed.
• A patient with stage 3 colon cancer, who had received four prior lines of therapy, achieved prolonged stable disease and continued treatment into the 6th dosing cycle.
• PAS-004 has a long half-life of approximately 70 hours, supporting once-daily or less frequent oral dosing.
• The drug's pharmacokinetic profile shows consistent plasma levels at steady-state, potentially reducing the risk of toxicity.
• The company believes PAS-004 has the potential to outperform current MEK inhibitors due to its safety, reduced administration frequency, and potential efficacy.

Sentiment

Score: 8

Explanation: The document presents very positive early results from a Phase 1 trial, with a focus on safety, tolerability, and a unique pharmacokinetic profile. The potential for less frequent dosing and improved efficacy compared to existing treatments is encouraging. However, it is still early in the development process, and future results are not guaranteed.

Positives

• The drug showed no treatment-related adverse events or dose-limiting toxicities in the first two cohorts.
• A patient with heavily pre-treated colorectal cancer showed prolonged stable disease.
• The long half-life of approximately 70 hours allows for less frequent dosing.
• The drug has a flat pharmacokinetic curve at steady-state, which may reduce peak plasma toxicities.
• PAS-004 has a distinct MEK inhibitor profile that may be advantageous for treating various conditions.

Risks

• The results are from an early-stage Phase 1 trial with a small sample size of six patients.
• Future clinical trial results may not match the positive results observed to date.
• The drug's efficacy needs to be confirmed in larger, more diverse patient populations.
• Regulatory approval is not guaranteed, and the drug may not reach the market.

Future Outlook

The company expects to provide additional trial updates on a periodic basis as the trial progresses and plans to advance PAS-004 into clinical trials for both the treatment of cutaneous and plexiform neurofibromas in NF1, cancer and other MAPK-driven opportunities.

Management Comments

• Dr. Tiago Reis Marques, CEO of Pasithea, stated that the data demonstrates a PK and safety profile that differentiates PAS-004 as a next-generation MEK inhibitor.
• Dr. Tiago Reis Marques also noted that the long half-life and ability to achieve a flat PK curve at steady-state aim to provide constant target inhibition while avoiding peak plasma toxicities.

Industry Context

This announcement is significant as it presents a potential advancement in MEK inhibitor therapy, particularly for NF1 and other cancers. Current MEK inhibitors often have limitations such as short half-lives and significant side effects. PAS-004's profile could address these issues.

Comparison to Industry Standards

• First-generation MEK inhibitors, such as those used for NF1 treatment, typically have half-lives of less than 8 hours, requiring twice-daily dosing.
• PAS-004 has a half-life of approximately 70 hours, potentially allowing for once-daily or less frequent dosing, which is a significant improvement.
• Existing MEK inhibitors often cause side effects like rash and gastrointestinal issues, which have not been observed with PAS-004 in this early trial.
• The ability to achieve stable plasma concentrations at steady-state with PAS-004 is a unique feature compared to other MEK inhibitors.

Stakeholder Impact

• Shareholders may view the positive early results as a positive sign for the company's future.
• Patients with NF1 and other cancers may benefit from the development of this new treatment.
• Employees of Pasithea may be encouraged by the progress of the clinical trial.
• The company's suppliers and partners may see potential for future business opportunities.

Next Steps

• The company has initiated cohort 3 dosing at an increased dose of 8 mg.
• The company has filed a protocol amendment to increase the dosing schedule.
• The company expects to provide additional trial updates on a periodic basis as the trial progresses.

Key Dates

Keywords

PAS-004, MEK inhibitor, Neurofibromatosis type 1, NF1, Cancer, Clinical trial, Pharmacokinetics, Safety, Efficacy, Drug development